KCT0006171
Recruiting
未知
A study to evaluate the impact of glucose variability on cardiovascular disease, sleep disorder, and diabetic complications in patients with type 2 diabetes
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Korea University Ansan Hospital
- Enrollment
- 110
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •° Patients with type 2 diabetes aged 19 to 80 years, and who will be treated with the following insulin and oral hypoglycemic medications.
- •\- Basal insulin: Levemir, Lantus, Tresiba, Toujeo
- •\- Prandial insulin: NovoRapid, Fiasp, Humalog, Apidra
- •\- Premixed insulin: Ryzodeg
- •° Hypoglycemic agents other than insulin
- •\- Metformin, Thiazolidinedione (Pioglitazone, Lobeglitazone, Rosiglitazone), Sulfonylurea (Glimepiride, Gliclazide, Glipizide, Glibenclamide), Meglitinide (Repaglinide, Nateglinide, Mitiglinide), DPP4 inhibitor (Sitagliptin, Linagliptin, Gemigliptin, Vildagliptin, Saxagliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin), GLP\-1 agonist (Exenatide, Lixisenatide, Liraglutide, Exenatide LAR, Albiglutide, Dulaglutide), SGLT\-2 inhibitor (Dapagliflozin, Empagliflozin, Ipragliflozin), a\-glucosidase Inhibitor (Acarbose, Voglibose)
- •° Fasting C\-peptide level measured at the hospital in the past 2 years is 0\.4\-3\.0ng/mL
Exclusion Criteria
- •Those who fall under any of the following criteria
- •° Insulin pump users
- •° Those who have been hospitalized for HHS (hyperglycemia hyperosmolar syndrome), DKA (Diabetic ketoacidosis), acute myocardial infarction, or stroke in the past 3 months
- •° Stage 4 or 5 of chronic renal disease (\< eGFR 30\)
- •° Patients with hepatic failure (AST or ALT \= 2\.5 times the upper normal limit) or symptomatic heart failure with pulmonary oedema
- •° Those who are currently receiving anticancer therapy, radiation therapy, and targeted therapy
- •° Those who are currently receiving the following medicines that may affect blood glucose
- •\- Steroid, immunosuppressive agents (cyclosporine, tacrolimus, and sirolimus), nicotinic acid \=1500mg/day, systemic isotretinoin, and anti\-obesity agents (liraglutide, orlistat, phentermine, phendimetrazine, mazindol)
- •\- Route of steroid administration: Oral administration and intravenous injection and joint injection are excluded from the study (A nasal spray or inhaler at maintenance dose may be used in this study)
- •° Patients with uncontrolled hypertension (SBP \=160 mmHg or DBP \=100 mmHg)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The effect of glucose variability, as assessed by continuous glucose monitoring system, on cardiovascular diseaseJPRN-UMIN000010620Yokohama City University Medical Center100
Not yet recruiting
Not Applicable
Correlation between glucose variability evaluated by CGMS and labile hemoglobin A1c measured by high performance liquid chromatography (HPLC) in Japanese patients with diabetes.diabetesJPRN-UMIN000030696St. Marianna University School of Medicine100
Completed
Not Applicable
Study for the effect of the blood glucose change of the appropriate glucide noodles (Ramen) using Free continuous Glucose Monitoring System (FGM).JPRN-UMIN000032148Sapporo diabetes, thyroid clinic22
Recruiting
Not Applicable
Analysis of the interplay between glucose variability, microbiomics and metabolomics in patients with multiple sclerosis during relapse and recoveryG35Multiple sclerosisDRKS00031852KSH, Kiel50
Completed
Not Applicable
Evaluation of the effects on blood glucose level in Japanese patients with type 2 diabetes who are on diet therapy: a randomized, double-blind, crossover trialJPRN-UMIN000032445ORTHOMEDICO Inc.12